
Inventiva S.A. (IVA) Stock Forecast & Price Target
Inventiva S.A. (IVA) Analyst Ratings
Bulls say
Inventiva SA, a biopharmaceutical company focused on developing innovative therapies, is advancing its lead product candidate, lanifibranor, for the treatment of non-alcoholic steatohepatitis (NASH), a condition currently lacking approved treatments. The positive outcomes related to metabolic markers and weight gain observed in high-risk subgroups suggest that lanifibranor could serve as a complementary therapy alongside GLP-1 medications, potentially enhancing its position in the market. Additionally, the company's collaborative research partnerships with AbbVie and BI remain a significant revenue source, while increased confidence in lanifibranor's efficacy and market penetration assumptions further contribute to a favorable outlook for Inventiva's stock.
Bears say
Inventiva SA's financial outlook appears negative due to significant turnover in key regulatory positions such as CEO and CMO, which may disrupt leadership stability and negatively influence share performance. The company reported a net loss of €175.9 million, or €1.62 per share, indicating financial challenges that could hinder future growth and operations. Furthermore, concerns regarding the efficacy and safety of its main clinical program, lanifibranor, in Phase III development, along with the potential for clinical trial failures and delays, present additional risks that may diminish investor confidence and impact stock performance.
This aggregate rating is based on analysts' research of Inventiva S.A. and is not a guaranteed prediction by Public.com or investment advice.
Inventiva S.A. (IVA) Analyst Forecast & Price Prediction
Start investing in Inventiva S.A. (IVA)
Order type
Buy in
Order amount
Est. shares
0 shares